Company Overview - Anika Therapeutics, Inc. (ANIK) is currently experiencing significant activity in the options market, particularly with the Jun 20, 2025 $10 Call option showing high implied volatility, indicating potential for a major price movement [1] Implied Volatility Insights - Implied volatility reflects market expectations for future stock movement, with high levels suggesting anticipation of a significant price change or an upcoming event that could trigger a rally or sell-off [2] Analyst Sentiment - Anika Therapeutics holds a Zacks Rank 3 (Hold) in the Medical - Biomedical and Genetics industry, which is in the top 33% of the Zacks Industry Rank. Over the past 60 days, no analysts have raised earnings estimates for the current quarter, while one has lowered the estimate, resulting in a decrease in the Zacks Consensus Estimate from 10 cents to 9 cents per share [3] Trading Strategy Implications - The high implied volatility surrounding Anika Therapeutics may indicate a developing trading opportunity. Options traders often seek to sell premium on options with high implied volatility, aiming to benefit from the decay of the option's value if the underlying stock does not move as much as anticipated [4]

Core Insights - Anika Therapeutics, Inc. will release its first quarter 2025 financial results on May 9, 2025, before market opening, followed by a conference call at 8:30 a.m. ET to discuss the results and business highlights [1] - The conference call will be accessible via a toll-free number for domestic calls and an international number, with a conference ID provided for participants [2] - Anika Therapeutics specializes in joint preservation and early intervention orthopedic care, focusing on areas such as Osteoarthritis Pain Management and Regenerative Solutions [3] Company Overview - Anika Therapeutics is a global company headquartered outside of Boston, Massachusetts, that leverages expertise in hyaluronic acid and implant solutions to provide minimally invasive products [3] - The company aims to restore active living for patients through its innovative orthopedic products, which are delivered efficiently in key care sites like ambulatory surgery centers [3]

Financial Performance - Revenue for the year ended December 31, 2024 was $119.9 million, a decrease of $0.9 million, or 1%, compared to the prior year[244]. - Gross profit for the year ended December 31, 2024 was $76.0 million, with a gross margin of 63%, down from $82.5 million and 68% in 2023[248]. - The loss from operations for the year ended December 31, 2024 was $5.1 million, compared to income from operations of $0.8 million in the prior year[252]. - Net loss for the year ended December 31, 2024 was $56.4 million, a decrease of $26.3 million, or 32%, compared to a net loss of $82.7 million in 2023[242]. - Adjusted gross profit for the year ended December 31, 2024 was $76.6 million, representing 64% of revenue, down from $83.3 million or 69% in 2023[258]. - Adjusted EBITDA for the year ended December 31, 2024 was $15.5 million, a decrease of $8.2 million compared to 2023, primarily due to lower adjusted gross profit and higher R&D spending[261]. - Adjusted net income from continuing operations for 2024 was $2.4 million, a decrease of $10.9 million compared to 2023, driven by higher manufacturing expenses and R&D costs[264]. Revenue Breakdown - Revenue from the OEM Channel decreased by 8% to $77.8 million for the year ended December 31, 2024, primarily due to lower sales from J&J MedTech[244]. - Revenue from the Commercial Channel increased by 17% to $42.1 million for the year ended December 31, 2024, driven by international sales growth of OA Pain Management products[246]. - Revenue for the year ended December 31, 2023 was $120.8 million, an increase of $7.0 million, or 6%, compared to the prior year, attributed to global adoption of OA Pain Management products and new product introductions[266]. - J&J MedTech accounted for 57% of revenue in 2024, down from 62% in the prior year, indicating a slight diversification in the customer base[275]. - Approximately $24.8 million of revenue was denominated in foreign currencies, primarily the Euro and UK pound sterling, for the year ended December 31, 2024[313]. Expenses - Research and development expenses increased by $3.7 million, or 17%, to $25.5 million for the year ended December 31, 2024, primarily due to compliance with regulatory requirements[249]. - Selling, general and administrative expenses decreased by $4.4 million, or 7%, to $55.6 million for the year ended December 31, 2024, attributed to lower headcount and reduced costs[251]. - Research and development expenses for the year ended December 31, 2023 were $21.8 million, an increase of $3.5 million, or 19%, primarily due to compliance with regulatory requirements and new product development[270]. - Selling, general and administrative expenses for the year ended December 31, 2023 were $59.9 million, an increase of $8.7 million, or 17%, mainly due to shareholder activism costs[271]. Cash Flow and Liquidity - Cash, cash equivalents, and investments totaled $55.6 million as of December 31, 2024, down from $68.7 million in 2023, with working capital decreasing from $132.3 million to $90.3 million[278]. - The company has a credit facility of up to $150.0 million, with no outstanding borrowings as of December 31, 2024 and 2023, indicating strong liquidity management[279]. - Cash provided by operating activities increased to $5.4 million in 2024 from a cash used of $(1.8) million in 2023, primarily due to a lower net loss[282]. - Cash used in investing activities rose to $8.3 million in 2024, up from $5.4 million in 2023, mainly due to increased capital expenditures for manufacturing capacity expansion[284]. - Cash used in financing activities increased significantly to $12.7 million in 2024 from $6.3 million in 2023, largely due to $10.9 million allocated for a stock repurchase program initiated in May 2024[285]. - The net decrease in cash and cash equivalents was $15.7 million in 2024, compared to a decrease of $13.5 million in 2023[280]. Future Plans and Investments - The company plans to launch the Integrity Implant System for rotator cuff repair in 2024 and is targeting FDA approval for key HA-based products like Cingal and Hyalofast[237]. - The company plans to continue investing in research and development for new products and clinical trials related to HA-based technology, funded by cash on hand and future operational cash generation[283]. - The company expects to fund future growth strategies through a combination of cash reserves and cash generated from operations[283]. Impairment and Leases - Impairment charges of $1.5 million were recorded for intangible assets related to the Arthrosurface reporting unit in 2024, following a $62.2 million impairment in 2023[309]. - The company has non-cancelable operating leases totaling $32.8 million, with $2.8 million due within one year[287]. Currency and Investment Management - The company does not engage in foreign currency hedging arrangements, exposing it to potential adverse effects from foreign currency fluctuations[313]. - The impact of currency exchange rate fluctuations related to international subsidiaries on financial statements was insignificant in 2024[313]. - The investment portfolio is managed to preserve principal, maintain liquidity, and obtain competitive returns without significantly increasing risk[312]. - The portfolio includes cash equivalents and investments in high-quality securities, such as money market funds and U.S. treasury bills[312]. - Unrealized gains or losses from the investment portfolio are reported as a separate component of accumulated other comprehensive income (loss)[312].

Financial Data and Key Metrics Changes - Overall revenue in Q4 was $30.6 million, up 1% compared to the same period in 2023. For the full year, revenue was $119.9 million, a slight decrease of 1% compared to 2023 [8][27] - Gross margin for the fourth quarter was 56%, down 13 points from last year. Adjusted gross margin was 58%, down 11 points versus last year [22] - Adjusted EBITDA from continuing operations was $3.6 million, down 44% compared to 2023 [23][29] - Total adjusted EBITDA for the company was in line with previously provided guidance, totaling $15.5 million for the full year [29] Business Line Data and Key Metrics Changes - Commercial channel revenue was up 25% in Q4 and 17% for the full year, while OEM channel revenue decreased by 8% for both the quarter and the full year [8][27] - Integrity sales grew by more than 40% sequentially for the third straight quarter, with over 1,000 surgeries performed globally since its launch [9][20] - Regenerative solutions in the commercial channel grew 32% year over year, contributing to future growth [20] Market Data and Key Metrics Changes - International OA pain management growth was 22% in Q4 and 16% for the full year, driven by geographic expansion and market share gains [8][27] - MONOVISC and ORTHOVISC remain market leaders in the U.S., despite competitive pricing pressures [21] Company Strategy and Development Direction - The company divested ArthroSURFACE and Parkus Medical to focus on core products with the best value-building opportunities [7] - The strategic focus is on expanding the Integrity implant system and advancing the HYALOFAST and CINGAL products [7][36] - The company aims to grow international OA pain products and Integrity domestically while seeking regulatory approvals for new products [36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's improved growth profile and solid financial structure, indicating no need for additional capital raising [37] - The company anticipates a challenging year for the OEM channel in 2025 but expects stability in pricing and market share in the following years [31][32] Other Important Information - The company generated $1.6 million in operating cash flow in Q4, down from $3.6 million last year, but improved cash flow management in the second half of 2024 led to $6.6 million in operating cash flow [25][30] - The company completed a $15 million share repurchase plan earlier than expected and ended Q4 with $56 million in cash and no debt [26] Q&A Session Summary Question: What were the one-time legacy program expenses referred to? - Management indicated that these were related to legacy product lines that will not continue, amounting to between $1 million and $2 million [40][41] Question: Is the SG&A of around $11 million to $12 million a good proxy for 2025? - Management confirmed that this is a good approximation for future SG&A expenses, reflecting the company's focus on hyaluronic acid [42] Question: What was the magnitude of the R&D charges for Hyalofast? - The one-time filing fee for Hyalofast was about $600,000, which is not expected to recur [43] Question: Will there be major R&D expenses for CINGAL in 2025? - Management stated that the bulk of the expenses for CINGAL are already accounted for, with ongoing work related to FDA feedback [46][48] Question: What is the expected growth driver for the commercial channel in the coming years? - The primary growth driver is expected to be the Integrity product, along with continued growth in international OA pain management [55][56]

Revenue Performance - Anika reported fourth quarter revenue from continuing operations of $30.6 million, a 1% increase compared to the same period in 2023[2]. - Full year 2024 total revenue from continuing operations was $119.9 million, a decrease of 1% relative to full-year 2023[3]. - Commercial Channel revenue increased by 17% year-over-year, while OEM Channel revenue decreased by 8% for the full year 2024[3]. - Revenue for Q4 2024 was $30,602 million, a 1.4% increase from $30,175 million in Q4 2023[29]. - For the three months ended December 31, 2024, total revenue was $30,602 million, a slight increase from $30,175 million in the same period of 2023[43]. - For the year ended December 31, 2024, total revenue was $119,907 million, slightly decreasing from $120,792 million in 2023[43]. Profitability and Margins - Adjusted EBITDA for the full year 2024 was $15.5 million, with an adjusted gross margin of 64%[10]. - Gross profit decreased to $17,125 million in Q4 2024, down 17.5% from $20,672 million in Q4 2023[29]. - Adjusted EBITDA for Q4 2024 was $3,586 million, down from $6,369 million in Q4 2023[36]. - The company reported an unadjusted gross margin of 56% for Q4 2024, down from 69% in Q4 2023[34]. - Gross profit for the year ended December 31, 2024, was $75,998 million, down from $82,532 million in 2023[43]. - Gross margin for the year ended December 31, 2024, was 63%, compared to 68% in 2023[43]. Expenses and Losses - Total operating expenses for Q4 2024 were $17,831 million, a decrease of 6.5% compared to $19,074 million in Q4 2023[29]. - Net loss for Q4 2024 was $21,865 million, significantly improved from a net loss of $63,000 million in Q4 2023[29]. - Adjusted net loss from continuing operations for Q4 2024 was $(332) million, compared to an adjusted net income of $980 million in Q4 2023[38]. Cash and Assets - Anika maintained a strong financial position with $55.6 million in cash and no debt at the end of the fourth quarter[10]. - Cash and cash equivalents decreased to $55,629 million in 2024 from $68,740 million in 2023[31]. - Total assets decreased to $202,740 million in 2024 from $270,632 million in 2023[32]. - Retained earnings dropped to $71,667 million in 2024 from $128,052 million in 2023[32]. Channel Performance - OEM Channel revenue for the three months ended December 31, 2024, was $19,669 million, accounting for 64% of total revenue, compared to 71% in the same period of 2023[43]. - Commercial Channel revenue increased to $10,933 million for the three months ended December 31, 2024, representing 36% of total revenue, up from 29% in the same period of 2023[43]. - The OEM Channel contributed $77,770 million for the year ended December 31, 2024, representing 65% of total revenue, down from 70% in 2023[43]. - The Commercial Channel generated $42,137 million for the year ended December 31, 2024, which is 35% of total revenue, an increase from 30% in 2023[43]. Growth and Strategic Initiatives - The Integrity Implant System achieved greater than 40% sequential growth for the third consecutive quarter, with over 1,000 surgeries performed globally since its launch[5]. - International OA Pain Management grew by 22% in the fourth quarter and 16% for the full year 2024, driven by geographic expansion and market share gains[5]. - Anika achieved significant regulatory milestones for Hyalofast, with a US launch anticipated by 2026[6]. - The company completed the strategic sale of Parcus Medical to focus on core HA products, enhancing resource allocation for growth opportunities[14]. - The company expects 2025 revenue guidance for the Commercial Channel to be between $47 million and $49.5 million, representing a 12% to 18% increase[13]. - The company is focusing on improving gross margins and exploring new market opportunities to enhance overall performance[43].

Company Performance - Avidity Biosciences reported a quarterly loss of $0.80 per share, which was better than the Zacks Consensus Estimate of a loss of $0.84, and compared to a loss of $0.79 per share a year ago, indicating an earnings surprise of 4.76% [1] - The company posted revenues of $2.97 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 29.26%, and this represents an increase from revenues of $2.19 million in the same quarter last year [2] - Over the last four quarters, Avidity Biosciences has surpassed consensus EPS estimates four times, but has only topped consensus revenue estimates once [2] Stock Outlook - The immediate price movement of Avidity Biosciences' stock will depend on management's commentary during the earnings call, with shares having added about 2% since the beginning of the year, outperforming the S&P 500's gain of 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.76 on revenues of $2.95 million, and for the current fiscal year, it is -$3.34 on revenues of $14.48 million [7] Industry Context - Avidity Biosciences operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - The performance of Avidity Biosciences' stock may also be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8]

Revenue Performance - Revenue for Q3 2024 was $38.75 million, a decrease of 7% compared to $41.47 million in Q3 2023[82] - Revenue for the first nine months of 2024 was $121.20 million, down 2% from $123.69 million in the same period of 2023[82] - Revenue from the OA Pain Management product family decreased by 2% for both Q3 and the first nine months of 2024 compared to the same periods in 2023[84] - Revenue from the Joint Preservation and Restoration product family decreased by 11% in Q3 2024 and by 1% in the first nine months of 2024 compared to the same periods in 2023[85] - Revenue from the Non-Orthopedic product family decreased by 24% and 11% for the three- and nine-month periods ended September 30, 2024, compared to the same periods in 2023[86] Profitability and Loss - Gross profit for Q3 2024 was $1.44 million, a significant decline of 94% from $24.94 million in Q3 2023, resulting in a gross margin of only 4%[82] - Gross profit for the three-month period ended September 30, 2024 decreased by $23.5 million to $1.4 million, and for the nine-month period, it decreased by $23.3 million to $53.4 million[87] - Gross margin for the three- and nine-month periods ended September 30, 2024 was 4% and 44%, respectively, down from 60% and 62% in the same periods of 2023[88] - Net loss for Q3 2024 was $29.92 million, a 355% increase from a net loss of $6.58 million in Q3 2023[82] - Net loss for the three- and nine-month periods ended September 30, 2024 was $29.9 million and $34.5 million, respectively, compared to a net loss of $6.6 million and $19.7 million in the same periods of 2023[94] - Adjusted net loss for the three months ended September 30, 2024, was $3.8 million, a decrease of $7.1 million compared to the same period in 2023[110] Expenses - Operating expenses for Q3 2024 totaled $29.46 million, a decrease of 10% compared to $32.62 million in Q3 2023[82] - Research and development expenses for the three- and nine-month periods ended September 30, 2024 were $7.2 million and $22.8 million, respectively, down from $7.8 million and $25.1 million in the same periods of 2023[89] - Selling, general and administrative expenses for the three- and nine-month periods ended September 30, 2024 were $19.1 million and $60.4 million, respectively, compared to $24.8 million and $75.5 million in the same periods of 2023[91] - A non-cash impairment charge of $3.1 million was recorded in the three-month period ended September 30, 2024, due to the decline in fair value of the Arthrosurface reporting unit[92] Cash Flow and Financial Position - Cash and cash equivalents were $62.4 million as of September 30, 2024, down from $72.9 million at December 31, 2023[113] - Cash provided by operating activities was $3.8 million for the nine-month period ended September 30, 2024, compared to cash used of $5.4 million in the same period in 2023[116] - Cash used in investing activities increased to $7.0 million for the nine months ended September 30, 2024, from $3.6 million in the same period in 2023[117] - Cash used in financing activities was $7.4 million for the nine months ended September 30, 2024, compared to $6.7 million in the same period in 2023[118] - The company has a credit facility of up to $150.0 million, with no outstanding borrowings as of September 30, 2024[114] Strategic Initiatives - The company completed the sale of Arthrosurface for a non-interest bearing promissory note of $7.0 million and potential future revenue payments based on sales performance[77] - The company plans to divest the Parcus Medical business to focus on core HA technology and regenerative solutions[78] - The company is actively engaging with the FDA for regulatory approval of Cingal, a next-generation OA pain management product[79] Adjusted Metrics - Adjusted gross profit for the three- and nine-month periods ended September 30, 2024 decreased to $25.0 million and $77.8 million, respectively, with adjusted gross margins of 65% and 64%[102] - Adjusted EBITDA for the three-month period ended September 30, 2024 increased by $0.7 million compared to the same period in 2023, while for the nine-month period, it increased by $4.5 million[105] - Adjusted diluted EPS for the nine months ended September 30, 2024, decreased by $0.38 to $(0.01) compared to $0.37 in the same period in 2023[112] Accounting Policies - There have been no significant changes to critical accounting policies or estimates since the last annual report[119] - The decrease in adjusted net income was primarily due to lower revenues from strategic ordering patterns with higher margin customers[111] Future Outlook - The company expects cash requirements to increase as operations expand, but believes current cash flows and resources are sufficient for ongoing investments[113]

Financial Data and Key Metrics Changes - Anika generated total revenue of $38.8 million in Q3 2024, a decrease of $2.7 million from the same period in 2023, primarily due to lower revenue from JNJ Medtech and softness in the Arthrosurface and Sports Medicine businesses [42][43] - Gross margin for the quarter was 4%, down from 60% last year, mainly due to a $23 million impairment from the Arthrosurface transaction [46] - Adjusted net loss was $3.8 million in the quarter, down from an adjusted net income of $3.3 million, primarily due to lower revenue and certain tax items [49] - The company ended Q3 2024 with $62.4 million in cash and no debt [51] Business Line Data and Key Metrics Changes - Revenue in the OA Pain Management segment decreased 2% to $24.4 million, primarily due to lower U.S. sales from JNJ [43] - Revenue from Joint Preservation and Restoration, including Arthrosurface and Parcus Medical, decreased 11% to $12 million, while Regenerative Solutions, including Integrity, grew 17% year-over-year [45] - Non-orthopedic revenue declined 24% to $2.4 million, aligning with prior guidance due to lower sales of mature products [46] Market Data and Key Metrics Changes - International OA Pain sales grew by 7%, with year-to-date international sales up 14%, indicating market share gains through geographic expansion [44] - The U.S. tendon augmentation market, where Integrity competes, is estimated to be over $220 million annually and grew about 13% in Q2 2024 [21] Company Strategy and Development Direction - Anika announced a renewed focus on differentiated HA-based products targeting the $4 billion market for OA pain management and Regenerative Solutions [8] - The company plans to reclassify revenue to provide clearer visibility into value drivers, separating revenue into commercial and OEM channels starting Q4 2024 [15][40] - A workforce reduction from approximately 325 to about 225 is expected to align with the updated strategic focus [14] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in the competitive and price-sensitive market but emphasized that their products still hold a market-leading position in the U.S. [37] - The company expects to deliver 16% growth at the midpoint of their guidance for 2024, driven by investments in HA-focused products [17] - Future guidance includes double-digit revenue growth in the commercial channel, with expectations of 12% to 18% growth in 2025 and 20% to 30% in 2026 and 2027 [55][60] Other Important Information - Anika signed and closed the sale of Arthrosurface for an estimated $10 million, with a planned divestiture of Parcus Medical [38] - The company recorded a one-time noncash impairment of Arthrosurface assets for approximately $27 million [39] - Adjusted EBITDA for Q3 was $5.4 million, up $700,000 from the prior year, as cost savings from restructuring efforts offset lower revenue [49] Q&A Session Summary Question: Will non-orthopedic revenue now be part of the commercial channel going forward? - No, it will be part of the OEM channel, similar to the JNJ relationship [67] Question: Can you provide guidance on gross margins in 2025? - It is too early to provide specific guidance as the company is still working on separating out the Arthrosurface and Parcus [68] Question: Will investments in the sales force for the commercial channel start right away? - Investments have already been made, focusing on direct sales reps, and will continue as new products are launched [69] Question: What will be the primary products in the commercial channel? - The primary products will include Monovisc, Orthovisc, Cingal, Hyalofast, and Integrity [72] Question: What is the expected revenue associated with the divested Arthrosurface business? - The revenue is around $25 million annually [74] Question: What is the global headcount reduction? - The reduction is from 325 to 225, including the impacts of Arthrosurface and Parcus [80]

Financial Performance - Anika reported third quarter revenue of $38.8 million, a decline of 7% compared to the same period in 2023[2]. - Revenue for Q3 2024 was $38,753,000, a decrease of 6.2% from $41,465,000 in Q3 2023[18]. - Total revenue for Q3 2024 was $24,428,000, a decrease of $460,000 or 2% compared to Q3 2023[25]. - Revenue for the first nine months of 2024 was $75,404,000, down by $1,451,000 or 2% from the same period in 2023[25]. - Overall revenue for the combined product families in Q3 2024 was $38,753,000, a decrease of $2,712,000 or 7% from Q3 2023[25]. - For the first nine months of 2024, combined product family revenue was $121,197,000, down by $2,494,000 or 2% from the same period in 2023[25]. Revenue Breakdown - U.S. OA Pain Management revenue decreased by 5% to $24.4 million, primarily due to reduced market access and competitive pricing pressures[2]. - Regenerative Solutions revenue increased by 17% to $2.7 million, driven by over 40% sequential growth in the Integrity Implant System, which was used in approximately 200 surgeries[3]. - The company expects Commercial Channel revenue growth of 14% to 19% in 2024, while OEM Channel revenue is projected to decline by 8% to 10%[8]. Expenses and Losses - Gross profit for Q3 2024 was $1,440,000, down 94.2% from $24,944,000 in Q3 2023[18]. - Total operating expenses decreased to $29,457,000 in Q3 2024 from $32,618,000 in Q3 2023, a reduction of 6.6%[18]. - Net loss for Q3 2024 was $29,918,000, compared to a net loss of $6,576,000 in Q3 2023, representing a significant increase in losses[18]. - Basic net loss per share for Q3 2024 was $(2.03), compared to $(0.45) in Q3 2023, indicating a significant decline in per-share performance[24]. Adjusted Metrics - Anika's adjusted EBITDA for 2024 is projected to be between $16 million and $18 million, impacted by lower U.S. OA Pain Management revenue and divestitures[9]. - Adjusted gross profit for Q3 2024 was $25,031,000, compared to $27,253,000 in Q3 2023, reflecting a decrease of 8.1%[21]. - Adjusted EBITDA for Q3 2024 was $5,431,000, an increase from $4,650,000 in Q3 2023, indicating improved operational performance[22]. Strategic Initiatives - The company announced the sale of Arthrosurface and plans to divest Parcus Medical to focus on core HA technology and Regenerative Solutions[6][7]. - The company plans to categorize revenue into Commercial Channel and OEM Channel starting in Q4 2024, with the Commercial Channel expected to achieve a CAGR of ~17% since 2021[1][5]. - The first module of the Hyalofast PMA was filed with the FDA on October 28, 2024, with a planned U.S. launch by 2026 targeting a $1 billion addressable market[3][6]. - Anika has repurchased $5.3 million of shares as part of a $40 million buyback program[6]. - The company anticipates long-term adjusted EBITDA margin expansion following the planned launch of Hyalofast by 2026[9]. Asset and Equity Changes - Cash and cash equivalents as of September 30, 2024, were $62,368,000, down from $72,867,000 at the end of 2023[19]. - Total assets decreased to $231,405,000 as of September 30, 2024, from $270,632,000 at the end of 2023, a decline of 14.5%[20]. - Stockholders' equity decreased to $179,864,000 as of September 30, 2024, from $212,265,000 at the end of 2023, a reduction of 15.3%[20].

y ANIKA Q2 2024 EARNINGS CALL AUGUST 8, 2024 Anika. Restore Active Living. SAFE HARBOR STATEMENTS Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company's commercial capabilities, initiatives and production, its product pipeline and associated timelines, its upcoming corporate milestones, and its growth strategy and projections, are forward looking statements within t ...